MARKET

ABEO

ABEO

Abeona Therapeut
NASDAQ
5.51
+0.32
+6.17%
After Hours: 5.55 +0.04 +0.73% 18:34 07/12 EDT
OPEN
5.20
PREV CLOSE
5.19
HIGH
5.60
LOW
5.20
VOLUME
631.06K
TURNOVER
0
52 WEEK HIGH
9.01
52 WEEK LOW
2.830
MARKET CAP
225.70M
P/E (TTM)
-1.7201
1D
5D
1M
3M
1Y
5Y
1D
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones
Abeona Therapeutics Inc.'s BLA resubmission of Pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa is expected 2nd half of 2024. If approved by the FDA, the company believes that it could reach peak U.S. Sales of >$500 million by year 5 of the gene therapy being sold. Abeona has already licensed out other gene therapies in its pipeline.
Seeking Alpha · 2d ago
Abeona Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
Abeona Therapeutics: Strong Buy Rating on Strategic Partnerships and Clinical Advancements
TipRanks · 2d ago
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target
Benzinga · 2d ago
Abeona inks research deal for gene therapy tech
Healthcare Abeona inks research deal for gene therapy tech. Abeona Therapeutics announced a partnership with eye care drug developer Beacon to evaluate its patented technology, AAV204, for gene therapies. The company is expected to receive an upfront payment for the deal.
Seeking Alpha · 3d ago
Abeona Therapeutics And Beacon Therapeutics Announced An Agreement By Which Beacon Will Evaluate Abeona's Patented AAV204 Capsid For The Development And Commercialization Of Potential Gene Therapies For Select Ophthalmology Indications
Beacon agrees to evaluate the AAV204 capsid for potential use in certain ophthalmology indications. Beacon has option to take a worldwide, non-exclusive license to use the capsid in connection with up to five gene or disease targets. Abeona will receive an upfront payment.
Benzinga · 3d ago
ABEONA THERAPEUTICS AND BEACON THERAPEUTICS ANNOUNCE NON-EXCLUSIVE AGREEMENT FOR BEACON TO EVALUATE THERAPEUTIC POTENTIAL OF ABEONA'S PATENTED AAV204 CAPSID FOR SELECT OPHTHALMOLOGY INDICATIONS
Reuters · 3d ago
ABEONA THERAPEUTICS: TO GET UPFRONT PAYMENT UPON BEACON'S EXERCISE OF OPTION TO LICENSE AAV204, WITH EXTRA PAYMENTS ON ACHIEVEMENT OF MILESTONES
Reuters · 3d ago
More
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Webull offers Abeona Therapeutics Inc stock information, including NASDAQ: ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.